Respiratory Syncytial Virus (RSV) has long been a formidable foe for infants, causing severe illness and hospital admissions worldwide. However, a recent study by researchers at UCL and Great Ormond Street Hospital for Children (GOSH) offers a glimmer of hope for better treatment options. The key insight? Targeting both the virus and the immune response is crucial for effective treatment.
The study, funded by Animal Free Research UK and UK Research and Innovation (UKRI), developed a unique lab model of baby lungs. This model, created using real infant airway cells, blood vessel cells, and neutrophils, allowed researchers to observe the early immune responses to RSV infection in a human setting.
One of the most fascinating findings was the difference in immune response between infants and adults. Baby airway cells attracted a significantly higher number of white blood cells, leading to blocked airways and breathing difficulties. The neutrophils in the infant model were more activated and triggered a stronger inflammatory reaction compared to the adult model.
"This suggests it's not just the virus that causes damage, but also the infant airway itself, which actively shapes the immune response," explains Dr. Machaela Palor, the first author of the study.
The researchers then tested two antiviral drugs, remdesivir and RSV604, and found that while both stopped viral multiplication, only RSV604 calmed the overactive immune response. This highlights the importance of considering the immune system's role in treatment strategies.
"Treating severe RSV in babies may require a two-pronged approach, targeting both the virus and the immune response," says Dr. Claire Smith, who led the study.
The new lab model provides a unique opportunity to assess potential treatments for their ability to control both aspects of the disease.
"Our model allows us to evaluate drugs not just for their antiviral properties but also for their impact on the immune response in the infant airway," Dr. Smith adds.
This study not only offers hope for better RSV treatments but also underscores the importance of age-specific considerations in respiratory infections. Understanding how infant airways shape immune responses will be crucial in designing safer and more effective treatments.
"This work is a testament to the power of human-specific research and its potential to revolutionize patient care," says Carla Owen, CEO of Animal Free Research UK.
With further research and development, this innovative approach could bring much-needed relief to families affected by RSV.
